JP2016506416A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016506416A5 JP2016506416A5 JP2015552058A JP2015552058A JP2016506416A5 JP 2016506416 A5 JP2016506416 A5 JP 2016506416A5 JP 2015552058 A JP2015552058 A JP 2015552058A JP 2015552058 A JP2015552058 A JP 2015552058A JP 2016506416 A5 JP2016506416 A5 JP 2016506416A5
- Authority
- JP
- Japan
- Prior art keywords
- epitope
- influenza
- derived
- immunogenic composition
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims description 41
- 102000036639 antigens Human genes 0.000 claims description 41
- 108091007433 antigens Proteins 0.000 claims description 41
- 239000000203 mixture Substances 0.000 claims description 34
- 229920001184 polypeptide Polymers 0.000 claims description 30
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 30
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 30
- 230000002163 immunogen Effects 0.000 claims description 29
- 241000712461 unidentified influenza virus Species 0.000 claims description 13
- 239000000185 hemagglutinin Substances 0.000 claims description 8
- 206010022000 influenza Diseases 0.000 claims description 8
- 101710154606 Hemagglutinin Proteins 0.000 claims description 6
- 241000712431 Influenza A virus Species 0.000 claims description 6
- 241000713196 Influenza B virus Species 0.000 claims description 6
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 6
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 6
- 101710176177 Protein A56 Proteins 0.000 claims description 6
- 101900234398 Influenza B virus Hemagglutinin Proteins 0.000 claims description 5
- 101900159346 Influenza A virus Hemagglutinin Proteins 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 241000710929 Alphavirus Species 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 229920002988 biodegradable polymer Polymers 0.000 claims description 2
- 239000004621 biodegradable polymer Substances 0.000 claims description 2
- 125000002091 cationic group Chemical group 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 239000011859 microparticle Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 description 4
- 229940124873 Influenza virus vaccine Drugs 0.000 description 3
- 239000007764 o/w emulsion Substances 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 229940126581 whole-virion vaccine Drugs 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 1
- 108010029566 avian influenza A virus hemagglutinin Proteins 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361751077P | 2013-01-10 | 2013-01-10 | |
| US61/751,077 | 2013-01-10 | ||
| PCT/EP2014/050414 WO2014108515A1 (en) | 2013-01-10 | 2014-01-10 | Influenza virus immunogenic compositions and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017229215A Division JP2018035195A (ja) | 2013-01-10 | 2017-11-29 | インフルエンザウイルス免疫原性組成物およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016506416A JP2016506416A (ja) | 2016-03-03 |
| JP2016506416A5 true JP2016506416A5 (enExample) | 2017-02-16 |
Family
ID=49956176
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015552058A Pending JP2016506416A (ja) | 2013-01-10 | 2014-01-10 | インフルエンザウイルス免疫原性組成物およびその使用 |
| JP2017229215A Pending JP2018035195A (ja) | 2013-01-10 | 2017-11-29 | インフルエンザウイルス免疫原性組成物およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017229215A Pending JP2018035195A (ja) | 2013-01-10 | 2017-11-29 | インフルエンザウイルス免疫原性組成物およびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20140193484A1 (enExample) |
| EP (1) | EP2943221A1 (enExample) |
| JP (2) | JP2016506416A (enExample) |
| CN (2) | CN104902925A (enExample) |
| AU (2) | AU2014204826A1 (enExample) |
| CA (1) | CA2897752A1 (enExample) |
| HK (1) | HK1214962A1 (enExample) |
| MX (1) | MX2015008847A (enExample) |
| RU (1) | RU2015132962A (enExample) |
| WO (1) | WO2014108515A1 (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013526849A (ja) | 2010-03-30 | 2013-06-27 | モウント シナイ スクール オフ メディシネ | インフルエンザウイルスワクチン及びその使用 |
| CN103153284B (zh) | 2010-07-06 | 2015-11-25 | 诺华股份有限公司 | 含有其pKa值有利于RNA递送的脂质的脂质体 |
| SI3243526T1 (sl) | 2010-07-06 | 2020-02-28 | Glaxosmithkline Biologicals S.A. | Dostava RNA za sprožitev večih imunskih poti |
| DK2591114T3 (en) | 2010-07-06 | 2016-08-29 | Glaxosmithkline Biologicals Sa | Immunization of large mammals with low doses of RNA |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| LT4226941T (lt) | 2010-08-31 | 2025-01-10 | Glaxosmithkline Biologicals Sa | Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui |
| PL3590949T3 (pl) | 2010-10-01 | 2022-08-29 | Modernatx, Inc. | Kwasy rybonukleinowe zawierające n1-metylo-pseudouracyle i ich zastosowania |
| BR112013008700B8 (pt) | 2010-10-11 | 2022-10-04 | Novartis Ag | Molécula de rna auto-replicante, partícula de replicon de alfavírus, composição, molécula de dna recombinante, uso da molécula de rna auto-replicante |
| DE12722942T1 (de) | 2011-03-31 | 2021-09-30 | Modernatx, Inc. | Freisetzung und formulierung von manipulierten nukleinsäuren |
| EP3854413A1 (en) * | 2011-07-06 | 2021-07-28 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP4241785A3 (en) | 2011-09-20 | 2023-09-27 | Icahn School of Medicine at Mount Sinai | Influenza virus vaccines and uses thereof |
| PT2791160T (pt) | 2011-12-16 | 2022-07-04 | Modernatx Inc | Composições arnm modificado |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| AU2013243955B2 (en) | 2012-04-02 | 2018-02-22 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9512456B2 (en) | 2012-08-14 | 2016-12-06 | Modernatx, Inc. | Enzymes and polymerases for the synthesis of RNA |
| CA2892529C (en) | 2012-11-26 | 2023-04-25 | Moderna Therapeutics, Inc. | Terminally modified rna |
| WO2014099931A1 (en) | 2012-12-18 | 2014-06-26 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccines and uses thereof |
| EP2968391A1 (en) | 2013-03-13 | 2016-01-20 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| WO2014159960A1 (en) | 2013-03-14 | 2014-10-02 | Icahn School Of Medicine At Mount Sinai | Antibodies against influenza virus hemagglutinin and uses thereof |
| EP2971010B1 (en) | 2013-03-14 | 2020-06-10 | ModernaTX, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| CA3177878A1 (en) | 2014-04-23 | 2015-10-29 | Modernatx, Inc. | Nucleic acid vaccines |
| US10736956B2 (en) | 2015-01-23 | 2020-08-11 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccination regimens |
| WO2016184822A1 (en) | 2015-05-15 | 2016-11-24 | Curevac Ag | Prime-boost regimens involving administration of at least one mrna construct |
| AU2016336344A1 (en) | 2015-10-05 | 2018-04-19 | Modernatx, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
| EP3365007A4 (en) * | 2015-10-22 | 2019-07-03 | ModernaTX, Inc. | WIDE SPECTRUM VACCINE AGAINST INFLUENZA VIRUS |
| CA3010974A1 (en) | 2016-01-11 | 2017-07-20 | Verndari, Inc. | Microneedle compositions and methods of using same |
| CN105664149A (zh) * | 2016-02-24 | 2016-06-15 | 华东理工大学 | 一种多抗原流感通用疫苗及其制备方法 |
| EP3471767A4 (en) | 2016-06-15 | 2020-01-15 | Icahn School of Medicine at Mount Sinai | Influenza virus hemagglutinin proteins and uses thereof |
| US12491261B2 (en) | 2016-10-26 | 2025-12-09 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| US11576961B2 (en) | 2017-03-15 | 2023-02-14 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| WO2018187706A2 (en) | 2017-04-07 | 2018-10-11 | Icahn School Of Medicine At Mount Sinai | Anti-influenza b virus neuraminidase antibodies and uses thereof |
| BR112019026615B1 (pt) * | 2017-06-15 | 2022-08-02 | Infectious Disease Research Institute | Carreadores lipídicos nanoestruturados e emulsões estáveis e usos dos mesmos |
| WO2018232357A1 (en) | 2017-06-15 | 2018-12-20 | Modernatx, Inc. | Rna formulations |
| CA3073020A1 (en) | 2017-08-16 | 2019-02-21 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| MX2020002348A (es) | 2017-08-31 | 2020-10-08 | Modernatx Inc | Métodos de elaboración de nanopartículas lipídicas. |
| CA3080656A1 (en) | 2017-10-30 | 2019-05-09 | Baxalta GmbH | Environmentally compatible detergents for inactivation of lipid-enveloped viruses |
| US12364746B2 (en) | 2018-06-21 | 2025-07-22 | Icahn School Of Medicine At Mount Sinai | Mosaic influenza virus hemagglutinin polypeptides and uses thereof |
| CA3109165A1 (en) * | 2018-08-17 | 2020-02-20 | Glaxosmithkline Biologicals Sa | Immunogenic compositions and uses thereof |
| JP2022501367A (ja) | 2018-09-20 | 2022-01-06 | モデルナティエックス インコーポレイテッドModernaTX, Inc. | 脂質ナノ粒子の調製及びその投与方法 |
| WO2020127730A1 (en) | 2018-12-20 | 2020-06-25 | Intervet International B.V. | Prime-boost vaccination regimen |
| JP2023502400A (ja) * | 2019-11-18 | 2023-01-24 | ザ・チルドレンズ・メデイカル・センター・コーポレーシヨン | がん免疫療法のために常在型樹状細胞を超活性化する刺激 |
| AU2021308681A1 (en) | 2020-07-16 | 2023-03-09 | Acuitas Therapeutics, Inc. | Cationic lipids for use in lipid nanoparticles |
| CN118647600A (zh) | 2021-12-16 | 2024-09-13 | 爱康泰生治疗公司 | 用于脂质纳米颗粒制剂的脂质 |
| TWI880664B (zh) * | 2023-03-10 | 2025-04-11 | 財團法人國家衛生研究院 | 流感病毒免疫原性組合物及使用其的方法 |
| AU2024270076A1 (en) * | 2023-05-10 | 2025-11-27 | Seqirus Inc. | Combination vaccine |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6015686A (en) * | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| CA2204254C (en) | 1994-11-17 | 2010-02-16 | Stephen Lewis Hart | Internalisation of dna, using conjugates of poly-l-lysine and an integrin receptor ligand |
| US6071890A (en) | 1994-12-09 | 2000-06-06 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy |
| US6451592B1 (en) * | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| US6090619A (en) | 1997-09-08 | 2000-07-18 | University Of Florida | Materials and methods for intracellular delivery of biologically active molecules |
| HUP0202846A3 (en) | 1999-09-24 | 2003-12-29 | Smithkline Beecham Biolog | Intranasal influenza virus vaccine |
| GB0024089D0 (en) | 2000-10-02 | 2000-11-15 | Smithkline Beecham Biolog | Novel compounds |
| EP1361889A1 (en) | 2001-02-23 | 2003-11-19 | GlaxoSmithKline Biologicals S.A. | Novel vaccine |
| DK1361890T3 (da) | 2001-02-23 | 2011-06-27 | Glaxosmithkline Biolog Sa | Influenzavaccineformuleringer til intradermal indgift |
| TWI228420B (en) | 2001-05-30 | 2005-03-01 | Smithkline Beecham Pharma Gmbh | Novel vaccine composition |
| DK1585812T3 (en) * | 2002-12-13 | 2017-04-10 | Alphavax Inc | MULTI-ANTI-ANTI-ANTI-VIRUS REPLICATE PARTICLES AND PROCEDURES |
| US7410795B2 (en) | 2002-12-23 | 2008-08-12 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection |
| KR101454842B1 (ko) * | 2003-03-20 | 2014-11-04 | 알파벡스, 인크. | 개선된 알파바이러스 레플리콘 및 헬퍼 구축물 |
| CA2529647C (en) * | 2003-06-16 | 2013-08-13 | Medimmune Vaccines, Inc. | Influenza hemagglutinin and neuraminidase variants |
| EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
| WO2005113756A1 (en) | 2004-05-14 | 2005-12-01 | Glaxosmithkline Biologicals S.A. | Method |
| ES2321212T3 (es) | 2004-05-18 | 2009-06-03 | Alphavax, Inc. | Vectores alfavirus derivados de tc-83, particulas y metodos antecentes de la invencion. |
| AU2005248361B2 (en) | 2004-05-18 | 2010-03-11 | Vical Incorporated | Influenza virus vaccine composition and methods of use |
| EP1766035B1 (en) | 2004-06-07 | 2011-12-07 | Protiva Biotherapeutics Inc. | Lipid encapsulated interfering rna |
| US8703095B2 (en) | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
| EP2037959B1 (en) * | 2006-06-07 | 2016-01-27 | The Trustees Of Princeton University | Cytomegalovirus surface protein complex for use in vaccines and as a drug target |
| WO2008039267A2 (en) * | 2006-07-21 | 2008-04-03 | Pharmexa Inc. | Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions |
| AU2007296489B2 (en) * | 2006-09-12 | 2013-07-04 | Alphavax, Inc. | Alphavirus replicon particles matched to protein antigens as immunological adjuvants |
| EA200900784A1 (ru) | 2006-12-06 | 2009-12-30 | Новартис Аг | Вакцины, включающие антиген из четырех штаммов вируса гриппа |
| EP2131848A4 (en) * | 2007-02-16 | 2012-06-27 | Merck Sharp & Dohme | COMPOSITIONS AND METHODS FOR REINFORCED ACTIVITY OF BIOLOGICAL ACTIVE MOLECULES |
| EA017887B1 (ru) * | 2007-08-02 | 2013-03-29 | Байондвакс Фармасьютикалз Лтд. | Полимерные мультиэпитопные вакцины против гриппа |
| WO2009132206A1 (en) | 2008-04-25 | 2009-10-29 | Liquidia Technologies, Inc. | Compositions and methods for intracellular delivery and release of cargo |
| RU2523587C2 (ru) * | 2008-07-11 | 2014-07-20 | МЕДИММЬЮН, ЭлЭлСи | Варианты гемагглютинина и нейрамидазы вируса гриппа |
| US20110280949A1 (en) * | 2008-08-06 | 2011-11-17 | Padma Malyala | Microparticles for use in immunogenic compositions |
| WO2011005799A2 (en) * | 2009-07-06 | 2011-01-13 | Novartis Ag | Self replicating rna molecules and uses thereof |
| US20120164176A1 (en) * | 2009-07-15 | 2012-06-28 | Kurt Swanson | Rsv f protein compositions amd methods for making same |
| JP5988492B2 (ja) * | 2009-09-02 | 2016-09-07 | ノバルティス アーゲー | Ｔｌｒ活性モジュレーターを含む免疫原性組成物 |
| JO3257B1 (ar) * | 2009-09-02 | 2018-09-16 | Novartis Ag | مركبات وتركيبات كمعدلات لفاعلية tlr |
| US9163068B2 (en) * | 2009-11-03 | 2015-10-20 | The United States of America as represented by the Secretary of the Department of Health and Human Services, National Institutes of Health, Office of Technology Transfer | Influenza virus recombinant proteins |
| WO2012082165A1 (en) * | 2010-01-24 | 2012-06-21 | Novartis Ag | Irradiated biodegradable polymer microparticles |
| EP3449910A1 (en) | 2010-07-06 | 2019-03-06 | GlaxoSmithKline Biologicals S.A. | Cationic oil-in-water emulsions |
| US9770463B2 (en) * | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
| LT2590676T (lt) | 2010-07-06 | 2016-10-25 | Glaxosmithkline Biologicals Sa | Viriono tipo išnešiojančios dalelės, skirtos besireplikuojančioms rnr molekulėms |
| DK2591114T3 (en) * | 2010-07-06 | 2016-08-29 | Glaxosmithkline Biologicals Sa | Immunization of large mammals with low doses of RNA |
| SI3243526T1 (sl) * | 2010-07-06 | 2020-02-28 | Glaxosmithkline Biologicals S.A. | Dostava RNA za sprožitev večih imunskih poti |
| US9192661B2 (en) * | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
| MX2013000163A (es) * | 2010-07-06 | 2013-03-05 | Novartis Ag | Metodos y composiciones inmunogenicas derivadas de norovirus. |
| CN103153284B (zh) * | 2010-07-06 | 2015-11-25 | 诺华股份有限公司 | 含有其pKa值有利于RNA递送的脂质的脂质体 |
| LT4226941T (lt) | 2010-08-31 | 2025-01-10 | Glaxosmithkline Biologicals Sa | Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui |
| WO2012031046A2 (en) | 2010-08-31 | 2012-03-08 | Novartis Ag | Lipids suitable for liposomal delivery of protein-coding rna |
| FI4043040T3 (fi) | 2010-08-31 | 2023-04-04 | Glaxosmithkline Biologicals Sa | Pieniä liposomeja immunogeeniä koodaavan rna:n toimittamiseksi |
| WO2012034025A2 (en) * | 2010-09-09 | 2012-03-15 | Virginia Commonwealth University | Human cytomegalovirus vaccine |
| BR112013008700B8 (pt) * | 2010-10-11 | 2022-10-04 | Novartis Ag | Molécula de rna auto-replicante, partícula de replicon de alfavírus, composição, molécula de dna recombinante, uso da molécula de rna auto-replicante |
| EP3527224B1 (en) * | 2011-01-26 | 2025-02-26 | GlaxoSmithKline Biologicals S.A. | Rsv immunization regimen |
| DK3275892T3 (da) * | 2011-05-13 | 2020-04-06 | Glaxosmithkline Biologicals Sa | Præfusions-rsv-f-antigener |
| WO2013006842A2 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic compositions and uses thereof |
| CN103764121A (zh) * | 2011-07-06 | 2014-04-30 | 诺华股份有限公司 | 用于递送rna分子的具有有用n:p比的脂质体 |
| CA2840965C (en) * | 2011-07-06 | 2021-03-02 | Novartis Ag | Cationic oil-in-water emulsions |
| ES2657547T3 (es) | 2011-07-06 | 2018-03-05 | Glaxosmithkline Biologicals Sa | Emulsiones aceite en agua que contienen ácidos nucleicos |
| EP3854413A1 (en) * | 2011-07-06 | 2021-07-28 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
| LT2750707T (lt) | 2011-08-31 | 2019-01-10 | Glaxosmithkline Biologicals Sa | Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui |
| AU2012322704B2 (en) * | 2011-10-11 | 2017-09-07 | Novartis Ag | Recombinant self-replicating polycistronic RNA molecules |
| US20140348863A1 (en) * | 2011-10-12 | 2014-11-27 | Alessia Bianchi | Cmv antigens and uses thereof |
| US9504747B2 (en) * | 2013-03-08 | 2016-11-29 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
-
2014
- 2014-01-10 CA CA2897752A patent/CA2897752A1/en not_active Abandoned
- 2014-01-10 EP EP14700356.0A patent/EP2943221A1/en not_active Withdrawn
- 2014-01-10 US US14/152,397 patent/US20140193484A1/en not_active Abandoned
- 2014-01-10 AU AU2014204826A patent/AU2014204826A1/en not_active Abandoned
- 2014-01-10 RU RU2015132962A patent/RU2015132962A/ru not_active Application Discontinuation
- 2014-01-10 HK HK16102971.1A patent/HK1214962A1/zh unknown
- 2014-01-10 MX MX2015008847A patent/MX2015008847A/es unknown
- 2014-01-10 WO PCT/EP2014/050414 patent/WO2014108515A1/en not_active Ceased
- 2014-01-10 JP JP2015552058A patent/JP2016506416A/ja active Pending
- 2014-01-10 CN CN201480004387.6A patent/CN104902925A/zh active Pending
- 2014-01-10 CN CN201811056155.1A patent/CN109045294A/zh active Pending
-
2017
- 2017-11-29 JP JP2017229215A patent/JP2018035195A/ja active Pending
-
2018
- 2018-11-13 AU AU2018260983A patent/AU2018260983A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016506416A5 (enExample) | ||
| RU2015132962A (ru) | Иммуногенные композиции на основе вируса гриппа и их применение | |
| WO2016109792A3 (en) | Novel multivalent nanoparticle-based vaccines | |
| JP2019526580A5 (enExample) | ||
| JP2018523668A5 (enExample) | ||
| JP2014503206A5 (enExample) | ||
| JP2019530462A5 (enExample) | ||
| JP2014534202A5 (enExample) | ||
| WO2020035609A3 (en) | Immunogenic compositions and uses thereof | |
| JP2017158561A5 (enExample) | ||
| JP2014532620A5 (enExample) | ||
| JP2015522540A5 (enExample) | ||
| JP2009539965A5 (enExample) | ||
| WO2016100807A3 (en) | Human antibodies to influenza hemagglutinin | |
| FI2970398T3 (fi) | Rsv f -prefuusioproteiineja ja niiden käyttö | |
| BR112016028816A8 (pt) | combinação imunogênica, método para obter uma resposta imunológica específica, uso de uma combinação imunogênica, e, regime de vacinação para prevenção, redução ou tratamento de infecção por vírus sincicial respiratório | |
| EA201990718A1 (ru) | Векторы аденовируса собачьих | |
| Slütter et al. | Cutting edge: rapid boosting of cross-reactive memory CD8 T cells broadens the protective capacity of the Flumist vaccine | |
| JP2017524682A5 (enExample) | ||
| JP2016520530A5 (enExample) | ||
| PH12020500569A1 (en) | Influenza virus vaccines and uses thereof | |
| FI3656395T3 (fi) | Menetelmiä ja koostumuksia suojaavan immuniteetin aikaansaamiseksi filovirusinfektiota vastaan | |
| JP2019531293A5 (enExample) | ||
| Fisher et al. | Virus-derived immunostimulatory RNA induces type I IFN-dependent antibodies and T-cell responses during vaccination | |
| JP2018501258A5 (enExample) |